The resurgence of tuberculosis concomitant with the emergence of resistant organisms to isoniazid and rifampicin has created an urgent need for newer antibuberculotic.

• 近年来由于全球结核病疫情回升，耐药结核菌呈增长趋势，尤其是耐异烟肼和/或利福平的复治病例逐渐增加，迫切需要研制新的高效抗结核药。